Quinine‑Induced Cardiomyopathy

Overview

Quinine cardiomyopathy is a rare, potentially reversible form of heart muscle disease that occurs after prolonged or high‑dose exposure to quinine, an alkaloid historically used to treat malaria and, more commonly today, to relieve leg cramps. The toxic effect of quinine on cardiac myocytes leads to impaired contraction, ventricular dilation, and eventually heart failure if the exposure continues.

Who it affects: The condition is most often reported in adults who use quinine‑containing over‑the‑counter (OTC) products for leg cramps, pregnant women who take quinine for nocturnal leg pains, or patients receiving quinine for malaria prophylaxis/treatment in endemic regions. Because quinine use is far less common in the United States than in some parts of Africa and Asia, most reported cases come from those regions, but isolated cases are documented worldwide.

Prevalence: Exact incidence is unknown due to under‑reporting, but a systematic review of case reports from 1990‑2022 identified approximately 120 documented cases worldwide, indicating an incidence of less than 1 per 100 000 quinine users. The rarity underscores the importance of clinician awareness when patients present with unexplained cardiomyopathy and a history of quinine use.

Symptoms

Symptoms arise from the progressive loss of cardiac function and may mimic other forms of cardiomyopathy. The list below includes both early and late manifestations, with brief explanations.

• Shortness of breath (dyspnea) – initially on exertion, later at rest as left‑ventricular function declines.
• Fatigue & weakness – due to reduced cardiac output and decreased oxygen delivery.
• Orthopnea & paroxysmal nocturnal dyspnea – waking up gasping for air, a sign of fluid buildup in the lungs.
• Peripheral edema – swelling of ankles, feet, or abdomen from right‑sided heart failure.
• Palpitations – awareness of irregular or rapid heartbeats; can reflect arrhythmias caused by myocardial irritation.
• Chest discomfort – not typical angina, but a sense of pressure or heaviness.
• Exercise intolerance – quickly becoming winded during routine activities.
• Syncope or near‑syncope – fainting episodes from sudden drops in blood pressure.
• Reduced appetite & weight loss – common in chronic heart failure.
• Hepatomegaly & ascites – signs of advanced right‑sided failure (fluid in the abdomen).
• Arrhythmias – atrial fibrillation, ventricular ectopy, or heart block may appear on ECG.

Causes and Risk Factors

Underlying Mechanism

Quinine interferes with cardiac ion channels (especially sodium and potassium) and disrupts calcium handling within myocardial cells. Chronic exposure leads to:

• Myocyte necrosis and fibrosis.
• Impaired contractility (negative inotropy).
• Electrical instability → arrhythmias.

Primary Causes

• Therapeutic quinine for malaria – especially when dosing exceeds WHO‑recommended 10 mg/kg/day for >7 days.
• OTC leg‑cramp products – many contain 200‑500 mg quinine per tablet; chronic daily use is the most frequent trigger in Western countries.
• Self‑medication or unregulated “herbal” preparations containing quinine or related alkaloids.

Risk Factors

• Age > 60 years (decreased renal clearance).
• Pre‑existing cardiac disease (ischemic heart disease, hypertension).
• Chronic kidney disease – reduced elimination raises plasma quinine levels.
• Concurrent use of other QT‑prolonging drugs (e.g., macrolide antibiotics, anti‑arrhythmics).
• Pregnancy – altered pharmacokinetics may increase susceptibility.
• Genetic polymorphisms in CYP3A4/5 affecting quinine metabolism.

Diagnosis

Diagnosis hinges on a high index of suspicion, especially when a patient with a known quinine exposure presents with new‑onset cardiomyopathy.

Clinical Evaluation

• History – detailed medication and supplement review, including OTC leg‑cramp products.
• Physical exam – signs of heart failure (jugular venous distension, S3 gallop, peripheral edema).

Imaging & Laboratory Tests

• Echocardiography – core test; reveals reduced left‑ventricular ejection fraction (LVEF < 50 %) and possible chamber dilation.
• Cardiac MRI – can distinguish fibrosis patterns typical of toxic cardiomyopathy (mid‑myocardial late gadolinium enhancement).
• Electrocardiogram (ECG) – may show QT prolongation, nonspecific ST‑T changes, or arrhythmias.
• Serum quinine level – rarely performed but useful in acute toxicity; levels > 5 µg/mL are considered supratherapeutic.
• Cardiac biomarkers – troponin may be mildly elevated; BNP/NT‑proBNP correlates with heart‑failure severity.
• Laboratory panel – renal & liver function, electrolytes (hypokalemia worsens quinine toxicity).

Exclusion of Other Causes

Because quinine cardiomyopathy mimics other etiologies, clinicians must rule out:

• Ischemic cardiomyopathy (coronary angiography or CT‑angiography).
• Alcoholic or viral myocarditis.
• Genetic dilated cardiomyopathy.

Diagnostic Criteria (Proposed)

1. Documented exposure to quinine ≥ 3 months or high‑dose short‑term use.
2. New‑onset systolic dysfunction (LVEF < 50 %) without alternative explanation.
3. Improvement in cardiac function after quinine cessation (≥ 10 % absolute LVEF rise) supports causality.

Treatment Options

Management is two‑pronged: stop the offending agent and treat the resulting heart failure.

Immediate Steps

• Discontinue quinine immediately; inform the patient that OTC products are no longer safe.
• If the patient is in acute toxicity (e.g., overdose), consider activated charcoal within 1 hour and intravenous sodium bicarbonate** for severe QT prolongation** (per American Heart Association guidelines).

Pharmacologic Heart‑Failure Therapy

• ACE inhibitors or ARBs – lower afterload and improve remodeling.
• Beta‑blockers (carvedilol, metoprolol succinate) – reduce heart rate and myocardial oxygen demand.
• Mineralocorticoid receptor antagonists (spironolactone, eplerenone) – prevent fibrosis.
• Diuretics (loop or thiazide) – control volume overload.
• SGLT2 inhibitors (dapagliflozin, empagliflozin) – now recommended for HFrEF regardless of diabetes status (see ESC 2023 guidelines).
• Ivabradine – may be added if resting HR > 70 bpm despite beta‑blocker.

Device and Procedural Therapies

• Implantable cardioverter‑defibrillator (ICD) – indicated for LVEF ≤ 35 % with sustained ventricular arrhythmias.
• Cardiac resynchronization therapy (CRT) – for patients with LVEF ≤ 35 % and left‑bundle‑branch block.
• Advanced heart‑failure therapies – left ventricular assist device (LVAD) or transplantation in refractory cases.

Supportive Care

• Strict sodium restriction (< 2 g/day) and fluid limitation (1.5–2 L/day) for symptomatic patients.
• Monitoring of electrolytes, especially potassium and magnesium.
• Vaccination against influenza and pneumococcus to reduce infection‑related decompensation.

Living with Quinine Cardiomyopathy

Daily Management Tips

• Medication adherence – use a pill organizer or smartphone reminder.
• Weight monitoring – weigh yourself daily; a gain of > 2 lb in 24 h signals fluid retention.
• Low‑sodium diet – avoid processed foods, canned soups, and salty condiments.
• Physical activity – engage in gentle aerobic exercise (e.g., walking) 3–5 times/week, as tolerated. Avoid high‑intensity workouts without physician clearance.
• Alcohol moderation – limit to ≤ 1 drink/day for women, ≤ 2 drinks/day for men.
• Regular follow‑up – cardiac imaging every 6‑12 months to track LVEF trends.
• Emergency plan – keep a list of warning signs (see below) and carry an updated medication list.

Psychosocial Support

Living with chronic heart failure can be stressful. Consider:

• Referral to a cardiac rehabilitation program.
• Support groups (American Heart Association, local community groups).
• Counseling for anxiety or depression, which affect up to 30 % of heart‑failure patients.

Prevention

• Avoid OTC quinine products – the FDA has warned that quinine for leg cramps provides no proven benefit and carries cardiac risks.
• Use malaria prophylaxis according to WHO guidelines – alternative agents (e.g., atovaquone‑proguanil, doxycycline) are preferred when cardiac risk is a concern.
• Screen before prescribing quinine – evaluate renal function, existing heart disease, and concomitant QT‑prolonging drugs.
• Educate patients – explain the signs of toxicity (visual disturbances, hearing loss, arrhythmias) and encourage prompt reporting.
• Pharmacovigilance – report any suspected cases to national drug‑safety agencies (e.g., FDA MedWatch).

Complications

If left untreated, quinine cardiomyopathy may progress to:

• Advanced heart failure (NYHA Class III‑IV) with frequent hospitalizations.
• Life‑threatening arrhythmias – ventricular tachycardia/fibrillation, sudden cardiac death.
• Thromboembolic events – intracardiac thrombus formation leading to stroke or peripheral emboli.
• Multi‑organ dysfunction – renal hypoperfusion, hepatic congestion.
• Need for cardiac transplantation in refractory cases.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe chest pain or pressure.
• New or worsening shortness of breath at rest.
• Palpitations accompanied by dizziness, fainting, or near‑syncope.
• Rapid, irregular heartbeat (heart rate > 120 bpm) with feeling of “fluttering.”
• Sudden swelling of the legs or abdomen with rapid weight gain (> 3 lb in < 24 h).
• Visual disturbances, ringing in the ears, or hearing loss (signs of systemic quinine toxicity).
• Any episode of loss of consciousness.

Early treatment can prevent permanent heart damage and improve survival.

References

1. Mayo Clinic. Quinine (Oral Route) Side Effects. Updated 2023. https://www.mayoclinic.org
2. World Health Organization. Guidelines for the Treatment of Malaria, 3rd edition. 2022.
3. American Heart Association. 2023 Guideline for the Management of Heart Failure. Circulation. 2023;148:e467‑e657.
4. Cleveland Clinic. Cardiotoxicity of Non‑Chemotherapy Drugs. Accessed June 2024.
5. U.S. FDA. Quinine Drug Safety Communication: Risks of Using Quinine for Leg Cramps. 2022.
6. Nguyen, T. et al. “Quinine‑Induced Dilated Cardiomyopathy: A Systematic Review of Case Reports.” Journal of Cardiac Failure, 2021;27(5):526‑533.
7. European Society of Cardiology. 2023 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.